{"id":994426,"date":"2026-08-12T17:55:53","date_gmt":"2026-08-12T21:55:53","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-reports-second-quarter-2026-financial-results-and-provides-corporate-update\/"},"modified":"2026-08-12T17:55:53","modified_gmt":"2026-08-12T21:55:53","slug":"aeon-biopharma-reports-second-quarter-2026-financial-results-and-provides-corporate-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-reports-second-quarter-2026-financial-results-and-provides-corporate-update\/","title":{"rendered":"AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>&#8211; Executed a $15.3 million financing with milestone warrants providing potential for an additional $34.0 million in gross proceeds, supporting continued advancement of ABP-450&#8217;s development program<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>&#8211; Upfront proceeds from financing provide cash runway into the first quarter of 2027<\/em>\n      <\/p>\n<p align=\"justify\">ALISO VIEJO, Calif., Aug.  12, 2026  (GLOBE NEWSWIRE) &#8212; AEON Biopharma, Inc. (\u201cAEON\u201d or the \u201cCompany\u201d) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX<sup>\u00ae<\/sup> (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today reported its financial results for the second quarter ended June 30, 2026, and provided a corporate update.<\/p>\n<p align=\"justify\">\u201cThe second quarter marked continued progress in advancing ABP-450 through the analytical phase of our biosimilar development program while also strengthening the Company&#8217;s financial position,\u201d commented Rob Bancroft, President and Chief Executive Officer of AEON. \u201cAs we enter the second half of 2026, our primary focus is obtaining FDA feedback on the next phase of development, including the clinical pharmacology and comparative clinical study requirements for ABP-450. With the successful completion of our recently oversubscribed public offering, AEON is well positioned to execute on our near-term regulatory and corporate objectives as we continue advancing our goal of bringing a biosimilar to BOTOX<sup>\u00ae<\/sup> to the therapeutic market.\u201d<\/p>\n<p align=\"justify\">\n        <strong>Second Quarter 2026 Highlights and Recent Developments<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Continued Advancement Toward BPD Type 2b Regulatory Feedback<\/strong><\/p>\n<ul type=\"circle\">\n<li>AEON held a successful Biosimilar Biological Product Development (BPD) Type 2a meeting with the U.S. Food and Drug Administration (FDA) during the first quarter of 2026. During the meeting, the Agency reviewed the Company&#8217;s proposed analytical similarity strategy under the 351(k) biosimilar pathway and provided feedback supporting AEON&#8217;s planned analytical development approach for ABP-450. Collectively, the FDA&#8217;s feedback provided AEON with well-defined direction and a framework for the remaining analytical components of its biosimilar development program. The Agency also acknowledged the unique scientific challenges associated with characterizing the 900 kDa botulinum neurotoxin complex due to its large size and exceptional potency, while providing constructive feedback on the Company&#8217;s proposed analytical assessment plan. The Company looks forward to feedback from its planned BPD Type 2b interaction with the FDA in the second half of 2026, which is expected to help inform the next phase of development for ABP-450, including clinical pharmacology and comparative clinical study requirements.\n<\/li>\n<\/ul>\n<\/li>\n<li>\n          <strong>Strengthened Balance Sheet through a $15.3 Million Financing with Milestone Warrants Providing Potential for an Additional $34.0 Million in Gross Proceeds <\/strong><\/p>\n<ul type=\"circle\">\n<li>In July 2026, the Company completed an underwritten public offering that included net upfront proceeds of approximately $13.6 million, and up to an additional $34.0 million in potential gross proceeds upon the cash exercise in full of the milestone warrants issued in the offering. Upfront proceeds from the offering are expected to provide cash runway into the first quarter of 2027.\n<\/li>\n<\/ul>\n<\/li>\n<li>\n          <strong>NYSE American Compliance Restored<\/strong><\/p>\n<ul type=\"circle\">\n<li>On August 3, 2026, the Company regained full compliance with NYSE American continued listing requirements, resolving previously identified deficiencies and maintaining its listing on the exchange.\n<\/li>\n<\/ul>\n<\/li>\n<li>\n          <strong>Presented Data and Advanced Scientific Engagement Supporting Analytical Similarity to BOTOX<sup>\u00ae<\/sup><\/strong><\/p>\n<ul type=\"circle\">\n<li>In April 2026, the Company presented a poster at the 2026 American Academy of Neurology (AAN) Annual Meeting entitled \u201cEstablishing Primary Structure Comparability Between ABP-450 (prabotulinumtoxinA) and OnabotulinumtoxinA (Botox<sup>\u00ae<\/sup>) to Support Biosimilarity.\u201d The poster expanded upon analytical data previously reported by the Company demonstrating identical primary amino acid sequence between ABP-450 and the reference product, based on 93.5%\u201399.3% peptide sequence coverage.\n<\/li>\n<li>In June 2026, the Company presented an Abstract at the American Headache Society (AHS) Annual Meeting entitled \u201cEstablishing Structural and Functional Comparability Between ABP-450 and OnabotulinumtoxinA to Support Biosimilarity.\u201d\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>Liquidity and Capital Resources <\/strong>\n      <\/p>\n<p align=\"justify\">The Company reported cash and cash equivalents of $3.4 million as of June 30, 2026, which does not include approximately $13.6 million of net proceeds from the underwritten public offering that was completed in July 2026. Including those proceeds, cash and cash equivalents are expected to fund operations into the first quarter of 2027, supporting continued advancement of the ABP-450 program including ongoing analytical and regulatory activities.<\/p>\n<p align=\"justify\">\n        <strong>ABP-450 Development Milestones &amp; Scientific and\/or Corporate Events<\/strong>\n      <\/p>\n<ul>\n<li>Second half 2026: Receipt of additional FDA feedback expected to inform the next phase of the ABP-450 biosimilar development program, including clinical pharmacology and comparative clinical study requirements.\n<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>About the U.S. Biosimilar Pathway<\/strong>\n      <\/p>\n<p align=\"justify\">Analytical similarity forms the scientific foundation of the 351(k) pathway and represents the most data-intensive phase of biosimilar development. When analytical comparability across critical quality attributes is robustly demonstrated, the FDA may reduce the scope of required clinical studies under its totality-of-the-evidence framework. Sponsors may also seek extrapolation to additional indications of the reference product when scientifically justified.<\/p>\n<p align=\"justify\">\n        <strong>About AEON Biopharma<\/strong>\n      <\/p>\n<p align=\"justify\">AEON Biopharma is a biopharmaceutical company pursuing full-label access to the U.S. therapeutic neurotoxin market via biosimilarity to BOTOX<sup>\u00ae<\/sup>. The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually, representing a major opportunity for biosimilar entry. ABP-450 is the same botulinum toxin complex currently approved and marketed for cosmetic indications by Evolus, Inc. under the name Jeuveau<sup>\u00ae<\/sup>. ABP-450 is manufactured by Daewoong Pharmaceutical in a facility that has been authorized by the U.S. Food and Drug Administration, Health Canada, and European Medicines Agency for the manufacture of third-party botulinum toxin products. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. To learn more about AEON, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PUjPIYhGelpn1KdsBVE1lfQqINUt6vdvWytgwQcl-yjuiV3m0Y1k7w75r3Yw9Dlfwluq2cYh_9OWPabtzsQLI0ACaJPuidJx9ENckoI0OBY=\" rel=\"nofollow\" target=\"_blank\">www.aeonbiopharma.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <em>The foregoing material may contain \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company\u2019s product development and business prospects, and can be identified by the use of words such as \u201cmay,\u201d \u201cwill,\u201d \u201cexpect,\u201d \u201cproject,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cpotential,\u201d \u201cshould,\u201d \u201ccontinue\u201d or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <em>Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) AEON\u2019s ability to continue to meet continued stock exchange listing standards; (ii) the Company\u2019s ability to obtain additional and sufficient financing; (iii) the Company\u2019s anticipated financial performance, including cash and cash equivalents; (iv) the Company\u2019s plans regarding any interactions with the FDA; (v) the outcome of any regulatory interactions; and (vi) other risks and uncertainties set forth in the section entitled \u201cRisk Factors\u201d and \u201cCautionary Note Regarding Forward-Looking Statements\u201d in the Company\u2019s filings with the SEC, which are available on the SEC\u2019s website at <\/em><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9JPrXLklgaH6zSuPo6Y18eM0oL-o1qPkbxAjFpMwcn8q3KeordRAAyp4W5lnR2F6g4DBwVg2ytdUBmeOj24Lh9lNfbJ8cJ4yk_wMX04qWpynLlQY9KBzx0qKv1bBZ1e7HeeswxarIVCxYM2-PWPfRymNsYJ4XbEzLVm6O2BAIANILweDbIG3SOMStDpC3fIsh31xz8OwGSp7U-CWB5zgzSsTqjGyOPl7XZp707t7cxU=\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <em>www.sec.gov<\/em><br \/>\n        <\/a><br \/>\n        <em>.<\/em>\n      <\/p>\n<p>\n        <strong>Contacts <\/strong>\n      <\/p>\n<p>\n        <strong>Investor Contact: <\/strong><br \/>\n        <br \/>Hershel Berry<br \/>Blueprint Life Science Group<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7VDfcj3Z08P0tiCgGpwmQ6QJIk6Z_Zu47pyrjzOSwRsTzythcA_Ld-qa7SHOWBTIOrIsXq6egRzqyEl4BGAA4rQ_EnPIs5tuglw_6EdsYJFLJCsv9wg-rZxPj8mYOjTL\" rel=\"nofollow\" target=\"_blank\">hberry@Bplifescience.com<\/a><\/p>\n<p>Source: AEON Biopharma<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"10\" style=\"width:100.006%;text-align: center;vertical-align: middle\">\n            <strong>AEON BIOPHARMA, INC.<\/strong><br \/>\n            <br \/>\n            <strong>CONDENSED CONSOLIDATED BALANCE SHEETS<\/strong><br \/>\n            <br \/>\n            <strong>(in thousands, except share data and par value amounts)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.9939%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:12.0144%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:11.8778%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.9939%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:13.0383%;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>June\u00a030,<\/strong>\n          <\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:12.9018%;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>December 31,<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.9939%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:13.0383%;border-bottom: solid black 1pt;padding-right: 0;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>2026<\/strong><br \/>\n            \n          <\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:12.9018%;border-bottom: solid black 1pt;padding-right: 0;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>2025<\/strong><br \/>\n            \n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.9939%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:13.0383%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:12.9018%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.9939%;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>ASSETS<\/strong>\n          <\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:12.0144%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:11.8778%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.9939%;vertical-align: bottom\">\n            <strong>Current assets:<\/strong>\n          <\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:12.0144%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:11.8778%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:71%;width:70.9939%;min-width:71%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Cash and cash equivalents<\/td>\n<td style=\"max-width:1%;width:1.02395%;min-width:1%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"max-width:1%;width:1.02395%;min-width:1%;vertical-align: bottom\">$<\/td>\n<td style=\"max-width:11%;width:10.9904%;min-width:11%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">3,431<\/td>\n<td style=\"max-width:1%;width:1.02395%;min-width:1%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"max-width:1%;width:1.02395%;min-width:1%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"max-width:1%;width:1.02395%;min-width:1%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"max-width:1%;width:1.02395%;min-width:1%;vertical-align: bottom\">$<\/td>\n<td style=\"max-width:11%;width:10.9904%;min-width:11%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">3,006<\/td>\n<td style=\"max-width:1%;width:0.887424%;min-width:1%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.9939%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Prepaid expenses and other current assets<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">562<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">392<\/td>\n<td style=\"width:0.887424%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.9939%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: bottom\">\n            <strong>Total current assets<\/strong>\n          <\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">3,993<\/td>\n<td style=\"width:1.02395%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">3,398<\/td>\n<td style=\"width:0.887424%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.9939%;vertical-align: bottom\">Property and equipment, net<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">123<\/td>\n<td style=\"width:1.02395%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">162<\/td>\n<td style=\"width:0.887424%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.9939%;vertical-align: bottom\">Operating lease right-of-use asset<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">931<\/td>\n<td style=\"width:1.02395%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">1,052<\/td>\n<td style=\"width:0.887424%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.9939%;vertical-align: bottom\">Other assets<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">863<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">948<\/td>\n<td style=\"width:0.887424%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.9939%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: bottom\">\n            <strong>Total assets<\/strong>\n          <\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:10.9904%;border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">5,910<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:10.9904%;border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">5,560<\/td>\n<td style=\"width:0.887424%;border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.9939%;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT<\/strong>\n          <\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:12.0144%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:11.8778%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.9939%;vertical-align: bottom\">\n            <strong>Current liabilities:<\/strong>\n          <\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:12.0144%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:11.8778%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.9939%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Accounts payable<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">$<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">2,697<\/td>\n<td style=\"width:1.02395%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">$<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">942<\/td>\n<td style=\"width:0.887424%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.9939%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Accrued clinical trials expenses<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">933<\/td>\n<td style=\"width:1.02395%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">1,426<\/td>\n<td style=\"width:0.887424%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.9939%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Accrued compensation<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">1,897<\/td>\n<td style=\"width:1.02395%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">2,872<\/td>\n<td style=\"width:0.887424%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.9939%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Other accrued expenses<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">1,815<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">1,657<\/td>\n<td style=\"width:0.887424%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.9939%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: bottom\">\n            <strong>Total current liabilities<\/strong>\n          <\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">7,342<\/td>\n<td style=\"width:1.02395%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">6,897<\/td>\n<td style=\"width:0.887424%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.9939%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Convertible notes at fair value, including related party amount of $1,755 and $34,600 at June\u00a030,\u00a02026 and December 31, 2025, respectively<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">1,755<\/td>\n<td style=\"width:1.02395%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">34,600<\/td>\n<td style=\"width:0.887424%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.9939%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Operating lease liability<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">757<\/td>\n<td style=\"width:1.02395%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">893<\/td>\n<td style=\"width:0.887424%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.9939%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Derivative liability<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:1.02395%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">14,879<\/td>\n<td style=\"width:0.887424%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.9939%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Warrant liabilities<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">11,367<\/td>\n<td style=\"width:1.02395%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">3,276<\/td>\n<td style=\"width:0.887424%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.9939%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Contingent consideration liability<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">27<\/td>\n<td style=\"width:1.02395%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">42<\/td>\n<td style=\"width:0.887424%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.9939%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Other liabilities<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">23<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:0.887424%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.9939%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: bottom\">\n            <strong>Total liabilities<\/strong>\n          <\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">21,271<\/td>\n<td style=\"width:1.02395%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">60,587<\/td>\n<td style=\"width:0.887424%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.9939%;vertical-align: bottom\">Commitments and contingencies<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:12.0144%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:11.8778%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.9939%;vertical-align: bottom\">\n            <strong>Stockholders\u2019 Deficit:<\/strong>\n          <\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:12.0144%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:11.8778%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.9939%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Class A common stock, $0.0001 par value; 1,040,000,000 and 500,000,000 shares authorized at June\u00a030,\u00a02026 and December 31, 2025, and 26,307,211 and 12,105,902 shares issued and outstanding at June\u00a030,\u00a02026 and December 31, 2025, respectively<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">10<\/td>\n<td style=\"width:1.02395%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">9<\/td>\n<td style=\"width:0.887424%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.9939%;vertical-align: bottom\">Additional paid-in capital<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">468,396<\/td>\n<td style=\"width:1.02395%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">415,783<\/td>\n<td style=\"width:0.887424%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.9939%;vertical-align: bottom\">Accumulated deficit<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">(483,767<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">)<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">(470,819<\/td>\n<td style=\"width:0.887424%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.9939%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: bottom\">\n            <strong>Total stockholders&#8217; deficit<\/strong>\n          <\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">(15,361<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">)<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">(55,027<\/td>\n<td style=\"width:0.887424%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.9939%;vertical-align: bottom\">\n            <strong>Total liabilities and stockholders&#8217; deficit<\/strong>\n          <\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:10.9904%;border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">5,910<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:10.9904%;border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">5,560<\/td>\n<td style=\"width:0.887424%;border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.9939%\">\u00a0<\/td>\n<td style=\"width:1.02395%\">\u00a0<\/td>\n<td style=\"width:1.02395%\">\u00a0<\/td>\n<td style=\"width:10.9904%\">\u00a0<\/td>\n<td style=\"width:1.02395%\">\u00a0<\/td>\n<td style=\"width:1.02395%\">\u00a0<\/td>\n<td style=\"width:1.02395%\">\u00a0<\/td>\n<td style=\"width:1.02395%\">\u00a0<\/td>\n<td style=\"width:10.9904%\">\u00a0<\/td>\n<td style=\"width:0.887424%\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p align=\"center\">\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"17\" style=\"width:100.006%;text-align: center;vertical-align: middle\">\n            <strong>AEON BIOPHARMA, INC.<\/strong><br \/>\n            <br \/>\n            <strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME<\/strong><br \/>\n            <br \/>\n            <strong>(in thousands, except share and per share data)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:44.0299%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:12.0144%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:12.0144%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:12.0144%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:11.7413%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:44.0299%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"7\" style=\"width:27.1006%;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>Three Months Ended<\/strong>\n          <\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"7\" style=\"width:26.8275%;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>Six Months Ended<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:44.0299%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"7\" style=\"width:27.1006%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>June\u00a030,<\/strong>\n          <\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"7\" style=\"width:26.8275%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>June\u00a030,<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:44.0299%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:13.0383%;border-bottom: solid black 1pt;padding-right: 0;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>2026<\/strong><br \/>\n            \n          <\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:13.0383%;border-bottom: solid black 1pt;padding-right: 0;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>2025<\/strong><br \/>\n            \n          <\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:13.0383%;border-bottom: solid black 1pt;padding-right: 0;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>2026<\/strong><br \/>\n            \n          <\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:12.7652%;border-bottom: solid black 1pt;padding-right: 0;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>2025<\/strong><br \/>\n            \n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:44.0299%;vertical-align: bottom\">Operating expenses:<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:12.0144%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:12.0144%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:12.0144%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:11.7413%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:44%;width:44.0299%;min-width:44%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Selling, general and administrative<\/td>\n<td style=\"max-width:1%;width:1.02395%;min-width:1%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"max-width:1%;width:1.02395%;min-width:1%;vertical-align: bottom\">$<\/td>\n<td style=\"max-width:11%;width:10.9904%;min-width:11%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">2,991<\/td>\n<td style=\"max-width:1%;width:1.02395%;min-width:1%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"max-width:1%;width:1.02395%;min-width:1%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"max-width:1%;width:1.02395%;min-width:1%;vertical-align: bottom\">$<\/td>\n<td style=\"max-width:11%;width:10.9904%;min-width:11%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">3,258<\/td>\n<td style=\"max-width:1%;width:1.02395%;min-width:1%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"max-width:1%;width:1.02395%;min-width:1%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"max-width:1%;width:1.02395%;min-width:1%;vertical-align: bottom\">$<\/td>\n<td style=\"max-width:11%;width:10.9904%;min-width:11%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">6,893<\/td>\n<td style=\"max-width:1%;width:1.02395%;min-width:1%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"max-width:1%;width:1.02395%;min-width:1%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"max-width:1%;width:1.02395%;min-width:1%;vertical-align: bottom\">$<\/td>\n<td style=\"max-width:11%;width:10.9904%;min-width:11%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">6,383<\/td>\n<td style=\"max-width:1%;width:0.750897%;min-width:1%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:44.0299%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Research and development<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">2,938<\/td>\n<td style=\"width:1.02395%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">1,064<\/td>\n<td style=\"width:1.02395%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">4,973<\/td>\n<td style=\"width:1.02395%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">1,889<\/td>\n<td style=\"width:0.750897%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:44.0299%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Change in fair value of contingent consideration<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">(10<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">)<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">16<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">(15<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">)<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">(3,472<\/td>\n<td style=\"width:0.750897%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:44.0299%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: bottom\">Total operating costs and expenses<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">5,919<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">4,338<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">11,851<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">4,800<\/td>\n<td style=\"width:0.750897%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:44.0299%;vertical-align: bottom\">Loss from operations<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">(5,919<\/td>\n<td style=\"width:1.02395%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">)<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">(4,338<\/td>\n<td style=\"width:1.02395%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">)<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">(11,851<\/td>\n<td style=\"width:1.02395%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">)<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">(4,800<\/td>\n<td style=\"width:0.750897%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:44.0299%;vertical-align: bottom\">Other (loss) income:<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:12.0144%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:12.0144%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:12.0144%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:11.7413%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:44.0299%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Change in fair value of convertible notes<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">(213<\/td>\n<td style=\"width:1.02395%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">)<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">(1,854<\/td>\n<td style=\"width:1.02395%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">)<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">(8,940<\/td>\n<td style=\"width:1.02395%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">)<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">(3,485<\/td>\n<td style=\"width:0.750897%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:44.0299%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Change in fair value of warrants<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">4,941<\/td>\n<td style=\"width:1.02395%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">(542<\/td>\n<td style=\"width:1.02395%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">)<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">9,597<\/td>\n<td style=\"width:1.02395%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">86,187<\/td>\n<td style=\"width:0.750897%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:44.0299%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Loss on issuance of warrants<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:1.02395%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:1.02395%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:1.02395%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">(75,644<\/td>\n<td style=\"width:0.750897%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:44.0299%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Loss on extinguishment of debt<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:1.02395%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:1.02395%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">(76<\/td>\n<td style=\"width:1.02395%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">)<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:0.750897%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:44.0299%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Loss on derivative liability<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:1.02395%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:1.02395%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">(1,743<\/td>\n<td style=\"width:1.02395%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">)<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:0.750897%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:44.0299%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Other income, net<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">36<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">92<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">65<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">195<\/td>\n<td style=\"width:0.750897%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:44.0299%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: bottom\">Total other loss, net<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">4,764<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">(2,304<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">)<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">(1,097<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">)<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">7,253<\/td>\n<td style=\"width:0.750897%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:44.0299%;vertical-align: bottom\">(Loss) income before taxes<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">(1,155<\/td>\n<td style=\"width:1.02395%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">)<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">(6,642<\/td>\n<td style=\"width:1.02395%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">)<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">(12,948<\/td>\n<td style=\"width:1.02395%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">)<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">2,453<\/td>\n<td style=\"width:0.750897%;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:44.0299%;vertical-align: bottom\">Income taxes<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:1.02395%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:0.750897%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:44.0299%;vertical-align: bottom\">Net (loss) income<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:10.9904%;border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">(1,155<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">)<\/td>\n<td style=\"width:1.02395%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:10.9904%;border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">(6,642<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">)<\/td>\n<td style=\"width:1.02395%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:10.9904%;border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">(12,948<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">)<\/td>\n<td style=\"width:1.02395%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:10.9904%;border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">2,453<\/td>\n<td style=\"width:0.750897%;border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:44.0299%;vertical-align: bottom\">Basic net (loss) income per share<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:10.9904%;border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">(0.02<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">)<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:10.9904%;border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">(0.60<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">)<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:10.9904%;border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">(0.28<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">)<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:10.9904%;border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">0.32<\/td>\n<td style=\"width:0.750897%;border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:44.0299%;vertical-align: bottom\">Diluted net (loss) income per share<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:10.9904%;border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">(0.02<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">)<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:10.9904%;border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">(0.60<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">)<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:10.9904%;border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">(0.28<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">)<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:10.9904%;border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">0.31<\/td>\n<td style=\"width:0.750897%;border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:44.0299%;vertical-align: bottom\">Weighted average shares of common stock outstanding used to compute basic net (loss) income per share<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">50,530,946<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">11,090,809<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">45,599,911<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">7,557,472<\/td>\n<td style=\"width:0.750897%;border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:44.0299%;vertical-align: bottom\">Weighted average shares of common stock outstanding used to compute diluted net (loss) income per share<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">50,530,946<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">11,090,809<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">45,599,911<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.02395%;border-bottom: double black 3pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.9904%;border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle;vertical-align: bottom\">7,848,566<\/td>\n<td style=\"width:0.750897%;border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <em><br \/>\n          <br \/>The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (\u201cU.S. GAAP\u201d).<\/em><br \/>\n        <em>The condensed consolidated financial statements include the accounts of the Company and its controlled subsidiaries.<\/em>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwODgzMiM3NzczMDg0IzIyMjE3Nzg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MGQwNWY3M2UtOGIzMC00YjBkLTk2MmQtYmRiNjdkYjA5YWJmLTEyMzMzMzEtMjAyNi0wOC0xMi1lbg==\/tiny\/AEON-Biopharma-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>&#8211; Executed a $15.3 million financing with milestone warrants providing potential for an additional $34.0 million in gross proceeds, supporting continued advancement of ABP-450&#8217;s development program &#8211; Upfront proceeds from financing provide cash runway into the first quarter of 2027 ALISO VIEJO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) &#8212; AEON Biopharma, Inc. (\u201cAEON\u201d or the \u201cCompany\u201d) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX\u00ae (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today reported its financial results for the second quarter ended June 30, 2026, and provided a corporate update. \u201cThe second quarter marked continued progress in advancing ABP-450 through the analytical phase of our biosimilar development program while also strengthening the Company&#8217;s &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-reports-second-quarter-2026-financial-results-and-provides-corporate-update\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-994426","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-reports-second-quarter-2026-financial-results-and-provides-corporate-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"&#8211; Executed a $15.3 million financing with milestone warrants providing potential for an additional $34.0 million in gross proceeds, supporting continued advancement of ABP-450&#8217;s development program &#8211; Upfront proceeds from financing provide cash runway into the first quarter of 2027 ALISO VIEJO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) &#8212; AEON Biopharma, Inc. (\u201cAEON\u201d or the \u201cCompany\u201d) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX\u00ae (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today reported its financial results for the second quarter ended June 30, 2026, and provided a corporate update. \u201cThe second quarter marked continued progress in advancing ABP-450 through the analytical phase of our biosimilar development program while also strengthening the Company&#8217;s &hellip; Continue reading &quot;AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-reports-second-quarter-2026-financial-results-and-provides-corporate-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-12T21:55:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwODgzMiM3NzczMDg0IzIyMjE3Nzg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeon-biopharma-reports-second-quarter-2026-financial-results-and-provides-corporate-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeon-biopharma-reports-second-quarter-2026-financial-results-and-provides-corporate-update\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update\",\"datePublished\":\"2026-08-12T21:55:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeon-biopharma-reports-second-quarter-2026-financial-results-and-provides-corporate-update\\\/\"},\"wordCount\":1542,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeon-biopharma-reports-second-quarter-2026-financial-results-and-provides-corporate-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwODgzMiM3NzczMDg0IzIyMjE3Nzg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeon-biopharma-reports-second-quarter-2026-financial-results-and-provides-corporate-update\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeon-biopharma-reports-second-quarter-2026-financial-results-and-provides-corporate-update\\\/\",\"name\":\"AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeon-biopharma-reports-second-quarter-2026-financial-results-and-provides-corporate-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeon-biopharma-reports-second-quarter-2026-financial-results-and-provides-corporate-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwODgzMiM3NzczMDg0IzIyMjE3Nzg=\",\"datePublished\":\"2026-08-12T21:55:53+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeon-biopharma-reports-second-quarter-2026-financial-results-and-provides-corporate-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeon-biopharma-reports-second-quarter-2026-financial-results-and-provides-corporate-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeon-biopharma-reports-second-quarter-2026-financial-results-and-provides-corporate-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwODgzMiM3NzczMDg0IzIyMjE3Nzg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwODgzMiM3NzczMDg0IzIyMjE3Nzg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeon-biopharma-reports-second-quarter-2026-financial-results-and-provides-corporate-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-reports-second-quarter-2026-financial-results-and-provides-corporate-update\/","og_locale":"en_US","og_type":"article","og_title":"AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Market Newsdesk","og_description":"&#8211; Executed a $15.3 million financing with milestone warrants providing potential for an additional $34.0 million in gross proceeds, supporting continued advancement of ABP-450&#8217;s development program &#8211; Upfront proceeds from financing provide cash runway into the first quarter of 2027 ALISO VIEJO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) &#8212; AEON Biopharma, Inc. (\u201cAEON\u201d or the \u201cCompany\u201d) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX\u00ae (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today reported its financial results for the second quarter ended June 30, 2026, and provided a corporate update. \u201cThe second quarter marked continued progress in advancing ABP-450 through the analytical phase of our biosimilar development program while also strengthening the Company&#8217;s &hellip; Continue reading \"AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-reports-second-quarter-2026-financial-results-and-provides-corporate-update\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-12T21:55:53+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwODgzMiM3NzczMDg0IzIyMjE3Nzg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-reports-second-quarter-2026-financial-results-and-provides-corporate-update\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-reports-second-quarter-2026-financial-results-and-provides-corporate-update\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update","datePublished":"2026-08-12T21:55:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-reports-second-quarter-2026-financial-results-and-provides-corporate-update\/"},"wordCount":1542,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-reports-second-quarter-2026-financial-results-and-provides-corporate-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwODgzMiM3NzczMDg0IzIyMjE3Nzg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-reports-second-quarter-2026-financial-results-and-provides-corporate-update\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-reports-second-quarter-2026-financial-results-and-provides-corporate-update\/","name":"AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-reports-second-quarter-2026-financial-results-and-provides-corporate-update\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-reports-second-quarter-2026-financial-results-and-provides-corporate-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwODgzMiM3NzczMDg0IzIyMjE3Nzg=","datePublished":"2026-08-12T21:55:53+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-reports-second-quarter-2026-financial-results-and-provides-corporate-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-reports-second-quarter-2026-financial-results-and-provides-corporate-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-reports-second-quarter-2026-financial-results-and-provides-corporate-update\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwODgzMiM3NzczMDg0IzIyMjE3Nzg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwODgzMiM3NzczMDg0IzIyMjE3Nzg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-reports-second-quarter-2026-financial-results-and-provides-corporate-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/994426","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=994426"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/994426\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=994426"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=994426"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=994426"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}